Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy.

Trial Profile

Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Vulvovaginal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Accrual to date is 6%, according to United Kingdom Clinical Research Network record.
    • 31 May 2012 Additional lead trial investigators added as reported by United Kingdom Clinical Research Network record.
    • 31 May 2012 New source identified and integrated (United Kingdom Clinical Research Network UKCRN927).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top